Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.